Resaphene Suisse AG, ISIN CH0367465439, WKN A2JG91, has been informed of the announcement of patent grant by the European Patent Office. In a novel procedure involving a combination of Tailor Made-Notched Music Training (TMNMT) and heat therapy, an initial clinical user observation showed an average relief of 54% within 4 weeks in patients with chronic subjective tonal decompensated tinnitus; in individual cases, a decrease of 100 percent (complete disappearance) was noted.
"We identified the heatable in-ear headphones we developed as the key to successful therapy. The next step is an extensive double-blind placebo-controlled study at a large university hospital, "says Anke Rauterkus, CEO of Resaphene Suisse AG.
As part of the highly complex procedure, the project management for patenting was replaced by a long-term experienced project manager by the Board of Directors. This led to a significant shortening of the process. The Board is now expecting the swift completion of the US patent application.
"We identified the heatable in-ear headphones we developed as the key to successful therapy. The next step is an extensive double-blind placebo-controlled study at a large university hospital, "says Anke Rauterkus, CEO of Resaphene Suisse AG.
As part of the highly complex procedure, the project management for patenting was replaced by a long-term experienced project manager by the Board of Directors. This led to a significant shortening of the process. The Board is now expecting the swift completion of the US patent application.
